Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely
Executive Summary
Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.
You may also be interested in...
UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals
Veopoz (pozelimab) approval showed the FDA was reassured that Regeneron’s contract manufacturer is ready to supply high-dose Eylea, a key product for the company as competition picks up.
Novartis Aims To Fly High In Kidney Disease With Chinook Buy
Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.